Publications

Integrative clinical and preclinical studies identify FerroTerminator1 as a potent therapeutic drug for MASH

 18
Integrative clinical and preclinical studies identify FerroTerminator1 as a potent therapeutic drug for MASH

Tags:

Previous Article

Human Schwann cell lipid dysregulation and plasma membrane perturbation in Charc...

Next Article

FerroTerminator1 as a potent therapeutic drug for MASH

Related Posts

Single-cell multi-omics map of human fetal blood in Down syndrome

Single-cell multi-omics map of human fetal blood in Dow...

 13

Redox regulation, protein S-nitrosylation, and synapse loss in Alzheimer’s and related dementias

Redox regulation, protein S-nitrosylation, and synapse ...

 27

Activation of lysosomal Ca2+ channels mitigates mitochondrial damage and oxidative stress

Activation of lysosomal Ca2+ channels mitigates mitocho...

 12